New drug target companion prognostic test for hormone therapy resistance
Monday, April 1, 2013 - 15:00
in Health & Medicine
A team of international cancer researchers has identified the signalling pathway that is over-activated in estrogen receptor-positive breast cancer cells that are resistant to hormone therapies such as tamoxifen, aromatase inhibitors or fulvestrant.